Beryl Drugs Limited

Beryl Drugs Ltd held its Extra-Ordinary General Meeting on May 11, 2026, with 46 members present. Shareholders passed three ordinary resolutions via e-voting and poll, including two director appointme

Beryl Drugs shareholders approved the regularisation of Mrs. Neha Sarda as an Independent Director for a 5-year term. The approval was granted at an Extraordinary General Meeting held on May 11, 2026,

Beryl Drugs shareholders approved the regularisation of Mr. Shailendra Pathak as Whole-Time Director for 5 years at an EGM held on May 11, 2026. Mr. Pathak was initially appointed by the board on Janu

Beryl Drugs Ltd held an EGM on May 11, 2026, approving three key resolutions. Members appointed Mr. Shailendra Pathak as a whole-time director of the company. Members appointed Mrs. Neha Sarda as a no

Beryl Drugs Limited filed a SEBI Regulation 7(2) insider trading continual disclosure on 25 March 2026. Promoter & Director Sudhir Sethi (DIN: 00090172) acquired 7,500 equity shares (0.14%) on-market

Beryl Drugs Ltd. files SEBI Regulation 29(2) disclosure for promoter Mr. Sudhir Sethi's open market share acquisition. Sudhir Sethi acquired 7,500 equity shares (0.14%) on 24-March-2026, raising his h

Beryl Drugs Ltd discloses insider trading Form C under SEBI PIT Regulations 2015 for promoter share acquisition. Promoter & Director Sudhir Sethi acquired 7,500 equity shares on BSE on 23 March 2026 f

Beryl Drugs Limited discloses promoter Sudhir Sethi's acquisition of 7,500 equity shares (0.14%) via open market on 23 March 2026. Post-acquisition, Sudhir Sethi's holding in Beryl Drugs rises from 9.

Beryl Drugs shareholders approved a material related party transaction with Aminova Infusions Pvt Ltd for product distribution. The transaction has a monetary value of ₹5 crore and a duration of 12 ye